WO2006042926A1 - Composition pour lutter contre le ronflement - Google Patents
Composition pour lutter contre le ronflement Download PDFInfo
- Publication number
- WO2006042926A1 WO2006042926A1 PCT/FR2005/002444 FR2005002444W WO2006042926A1 WO 2006042926 A1 WO2006042926 A1 WO 2006042926A1 FR 2005002444 W FR2005002444 W FR 2005002444W WO 2006042926 A1 WO2006042926 A1 WO 2006042926A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- substance
- bioadhesive
- carrageenans
- pharynx
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
Definitions
- the present invention relates to the field of the treatment of snoring, and more particularly to a composition for controlling snoring.
- Snoring is noise due to the passage of air through narrowed airways in the pharynx. It reflects the vibration of the soft palate and the walls of the pharynx under the action of abnormally turbulent airflow.
- the inspiratory air passes, between the nasal cavity and the trachea, both rigid and indeformable, a deformable space, elastic and more or less narrowed.
- this narrowing will appear changes in flow and pressure that will lead to a vibration of the soft palate related to the clatter of it against the walls of the pharynx (Venturi phenomena).
- the soft veil touches the posterior wall of the pharynx, that it is pushed back by a current of air coming from the nose, then that a force any one brings him back to the palace.
- this force is the voluntary contraction.
- passive nocturnal snoring in the supine position this force is that of gravity, and when it is applied to a large and long veil, it spontaneously tends to stick to the pharynx.
- the appearance of snoring is due to several factors independent of each other, namely the existence of a too long veil, a falling asleep on the back and a narrowing of the rhino-pharynx following loosening of tissue and edema .
- the first factor responsible for the appearance of snoring is the existence of a too long veil caused by an enlargement of the veil: the uvula extends, the posterior pillars of the tonsils thicken and widen into two half curtains prolonging the veil down.
- This hypertrophy is related to the overweight that infiltrates fat tissues, but also to age. This phenomenon starts in the forties. However, it remains exceptional before this age, snoring being in this case related to the existence of a veil naturally very developed.
- the second factor responsible for the onset of snoring is the supine position (the position on the back of the sleeping body). This position causes the relaxed veil to rest on the posterior wall of the pharynx. In this anatomical position, the passage of nasal inspiratory air can easily lift the veil, make it float and vibrate. On the other hand, when the sleeper is lying on its belly, the veil falls forward so that the risk of touching the posterior or even lateral wall of the pharynx is removed; thus clear, the veil leaves wide open behind him the air corridor which is posterior to him, the air passing easily.
- the last element responsible for snoring concerns the narrowing of the oral cavity. This narrowing is caused by obesity, nasal obstruction and retrognathism. Obesity is particularly common among snorers. It causes quickly, even when it is light, a narrowing of the free space of the pharynx. Indeed, the overweight subject develops not only its overweight to the outside, but also to naturally free indoor spaces, namely essentially the mouth, neck and regions surrounding the upper airways. The congestive pharynx of the overweight subject in his fifties is very characteristic, huge and full, red and swollen.
- the alcohol taken at dinner also promotes snoring by congesting all the upper aerodigestive mucosa, that is to say, especially those of the nose and pharynx, and causing relaxation of the tissues by its anti-spasmodic properties.
- snoring is aggravated by sleeping pills.
- Other factors besides obesity or alcohol can also contribute to this narrowing of the pharyngeal space. It may be for example certain pathological hypertrophies of the language. Retrognathism is a shortness of the mandible which, more or less importantly, narrows the pharynx in the anteroposterior direction, and thus promotes the vibration of the uvula and soft tissues. Indeed, when the lower jaw is short and the chin is thrown back, the tongue whose attachment points are thus pushed back, tilts and obstructs the breathing more easily.
- the first disadvantage relates to the risk of passage of oil droplets into the lungs responsible for oily pneumonitis, which represents an undesirable effect with serious consequences for health.
- the second disadvantage relates to the duration of action of these products.
- the mixture is indeed sprayed on the mucus layer, which has an intrinsic velocity and causes the product to the stomach, outside its site of action.
- the natural phenomenon of swallowing and saliva production reinforces the elimination of oils from their site of action. This is the reason why these products are only satisfactory for a few minutes at the beginning of the night, but in no case during the whole of the night and especially in the middle of the night, during the deep sleep, and towards the end of the night. the night.
- This preparation contains edible oils (olive, sunflower ...) encapsulated in liposomes based on soy lecithin.
- This preparation administered at bedtime is intended to lubricate the back groove to facilitate the passage of air during breathing in the horizontal position.
- a number of in vitro tests have been carried out to demonstrate the persistence or non-persistence of the product over time on a biological membrane.
- the reference substance chosen was distilled water, considered as non-adhesive on physical or biological supports.
- the spreading time is the time taken by a defined volume of liquid to travel 10 centimeters on a plane inclined at 45 ° C.
- the purpose of the saliva immersion test is to highlight the contact time of the product with the biological membrane when subjected to the action of saliva.
- the purpose of the release test is to highlight the time it takes the product to release a tracer when it is subjected to permanent "leaching" by saliva.
- the present invention therefore intends to overcome the drawbacks of the prior art by proposing a combination of active agents and any other agent that will act on the level of the mucous membranes of the pharynx so as to reduce, or even eliminate, the noise of snoring in a certain way and measurable throughout the duration of sleep.
- the object of the present invention is to propose a composition having adhesion properties to mucocillary cells in order to limit the action of elimination of the assets of the composition generated by the velocity of the mucus, and in particular to limit the removal of active ingredients to lubricate the walls of the pharyngeal mucosa.
- the present invention also aims to provide a composition for treating the side effects caused by snoring, these side effects contributing in turn to the increase of snoring.
- This is inflammation and edema of pharyngeal tissue as well as loosening of the lining of the pharynx.
- the present invention is remarkable, in its broadest sense, in that it comprises at least one lubricating substance for lubricating the walls of the mucous membranes of the pharynx and at least one bioadhesive substance capable of adhering said lubricating substance.
- mucocilliary cells located at the level of the pharynx.
- the inventors have found that the compounds used in the composition according to the invention have complementary modes of action thus offering a synergy for a more effective action.
- the inventors have demonstrated the synergy between the lubricating substance and the bioadhesive substance for a more effective bioadhesiveness.
- bioadhesive substance is meant a biological or synthetic substance capable of "sticking" to a mucous membrane.
- Mucus is a superficial viscous layer of the pharyngeal tissues.
- mucus The function of mucus is to capture the particles inhaled by respiration (dust, viruses, bacteria, fungi ...), to allow their elimination to the stomach, to protect the lining of the respiratory tract against irritants or desiccation.
- mucus plays a very important role in local immunity mechanisms. Mucus, which is the first barrier to the entry into the body of foreign elements is in permanent renewal in order to eliminate as quickly as possible all the particles inhaled or ingested. The permanent renewal of the mucus is therefore a factor of rapid elimination of the ingredients delivered in the pharynx.
- the mucus is composed of two layers, namely: • A superficial viscous layer, which captures the particles, formed with 60-70% mucins (various insoluble substances secreted by goblet cells and submucosal glands) and 30-40% proteins (especially molecules involved in immunity such as transferrin, lysozyme, interferon, kallikrein, immunoglobulins ...); " A deep fluid layer composed of water-soluble elements and forming an aqueous medium allowing the flapping of the eyelashes, which propel the superficial layer towards the pharynx.
- mucus One of the properties of mucus is mucocilliary clearance, the combined action of mucus and eyelashes of the respiratory mucosa to remove foreign particles. This action is the consequence of eyelashes.
- These eyelashes bathe in the deep fluid layer, and have at their ends a small structure resembling a hook, which is implanted in the superficial viscous layer of mucus during movement.
- the eyelashes beat synchronously, the movement being made quickly to go (towards the pharynx), and more slowly to return.
- the eyelashes beat at about 1000 counts / min, and push the mucus towards the pharynx at a velocity of about 5-20 mm / min.
- the assets of a classic product projected on mucus travel an average of 1 cm per minute. It takes on average 15 minutes for the mucus containing the assets has left its site of action at the level of the pharynx and thus loses its effectiveness.
- the effectiveness of the composition against snoring can be obtained, unlike the products of the prior art, over a long period.
- the bioadhesive substance is chosen from the group comprising: polysaccharides, cellulose derivatives, acrylic derivatives or protein derivatives, or any other agent known to date as a bioadhesive agent.
- the bioadhesive substance is advantageously a polysaccharide (natural polymer) belonging to the carrageenan family.
- Carrageenans are polysaccharides that constitute the cell walls of various red algae (Rhodophyceae) belonging to the families Gigartinaceae, Hypneaceae, Furcellariaceae and Polyideaceae. They have long galactan chains, anionic polyelectrolytes. Their molecular weight may be greater than 10 6 Daltons.
- the bioadhesion property is generated by an interaction between the polysaccharides and the mucus covering the mucous membranes of the pharynx. Indeed, because of their chemical nature (high molecular weight polymers), polysaccharides are hungry for water. In contact with the mucus, which is highly hydrated and has a certain viscosity due to the presence of mucin, the polysaccharides swell rapidly with creation of hydrogen bonds between the hydrophilic groups of the polymer and those of mucin. This bioadhesion property is then enhanced by the formation of additional bonds due to the sulfate function of the carrageenans.
- the sulphate groups of the carrageenans which are particularly reactive, give rise to complexing reactions between the sulphate groups of the polysaccharide and the nitrogen atoms of the mucin, thus forming additional bonds to the hydrogen bonds, referred to as complexation bonds.
- lambda- and iota-carrageenans are used in the invention.
- carrageenans is therefore to allow the active ingredients contained in the anti-snoring composition, and in particular the lubricating substance, to remain at their site of action for a long time (duration greater than or equal to 8 hours).
- a surfactant or any other agent or combination of lubricating agents known to date.
- the surfactants or surfactants are molecules of natural or synthetic origin having on the one hand a lipophilic chain (or hydrophobic part) and on the other hand a hydrophilic group (polar part). These compounds are said to be amphiphilic.
- the polar part of the surfactant is chosen from the group comprising glucose, sucrose, lactose, glycerol, xylose, peptides, amino acids, nucleotides, the hydrophobic part being chosen from the group comprising fatty acids, a fatty alcohol, a fatty amine, esters, glycerides, phospholipids.
- the hydrophobic portion consists of phosphatidylcholine which is part of the family of phospholipids which are major compounds of the membranes surrounding the cells. As it helps maintain the integrity of these membranes and their "repair", it plays a vital role in the proper functioning of the body.
- phosphatidylcholine is a major component of bile and plays a role in fat metabolism.
- the composition further comprises one or more agent (s) anti-inflammatory (s) and / or tonic (s) of the mucous membranes and tissues.
- the anti-inflammatory agent chosen is advantageously an extract of Filipendula ulmaria, and preferably an extract of flowering heads of Filipendula ulmaria, which contain a set of components including flavonoids. and other phenolic glycosides.
- tannin rich plant extracts are preferably used so as to impart astringency properties to mucous membranes and pharyngeal tissues.
- the tonic agent chosen is advantageously rose hips.
- the rose hip is an elongated fruit of a shrub called Rosa canina (rose hips).
- extracts selected as anti-inflammatory and tonic agents are given by way of example. It may indeed be used in the composition object of the present invention any other agent for reducing inflammation and edema and / or increase the tone of the mucosa and tissues of the pharynx.
- composition according to the invention comprises selected active agents having lubrication properties of the mucous membranes of the pharynx over a long period, associated with a strengthening of the mucosal tone and an anti-inflammatory action.
- the substances chosen will be hypoallergenic substances.
- composition will advantageously comprise an excipient or will have a formulation general, adapted to the intended mode of administration.
- the composition according to the invention is in the form of a foam delivered orally.
- a foam can be obtained by dispersing a gas in a small volume of liquid causing the appearance of bubbles whose size can vary between 50 microns and several millimeters.
- the foam constitutes a specific galenic form suitable for optimal impregnation of the mucous membranes.
- the foam has spreading properties on the mucous membranes greater than the liquid form that tends, as soon as it is projected into the mouth, to sink to the bottom of the throat.
- the foam makes it possible to considerably increase the contact area between two incompatible surfaces. Indeed, one of the difficulties encountered in designing a liquid formulation to be dispersed on a biological membrane is often the incompatibility between the two surfaces.
- mucin is a protein that provides structural protection in the airways and digestive tract primarily.
- carrageenans to interact with mucin and epithelial cells must be placed in aqueous solution, physically incompatible with the mucin layer.
- the foam form thus has the advantage of allowing a contact between the carrageenans of the solution and the epithelial cells, thus allowing to reinforce the bioadhesion.
- Tests thus show in several experiments that the foam form has a bioadhesive power greater than the delivered liquid form. in the same quantities. In addition, tests have shown that the foam forms better "lining" the mucous membranes of the throat and pharynx. These same tests also show that the contact time between the foam and the mucous membranes is greater than that of a liquid form.
- Another advantage is a longer maintenance of the structure of the foam thanks for example to certain molecules contained in the plant extracts associated with the formulation of the product.
- Certain types of molecules contained in the plant extracts used in the formulation favor the stability over time of the foam form by phenomena of physicochemical interactions.
- a foam form would be more stable over time thanks to the action of flavonoid-type compounds.
- This stability over time reinforces the property enumerated above by allowing a longer contact time between the solution and the epithelial cells of the mucous membranes of the pharynx.
- the foam form has another advantage that is not to diffuse droplets in the airways, as is the case in conventional forms of spraying spray liquids. These droplets are indeed responsible for damage to the lungs and bronchi.
- oily preparations dispersed in the form of spray it has been found the appearance of oily pneumopathies with consequences very harmful to the health of individuals.
- Oily pneumopathies are diffuse pulmonary, paused, symptomatic, with radio-nodular aspects, predominating at the bases or localized pneumonitis pseudo-tumoral or oily granuloma. The prognosis is serious and the evolution irreversible.
- spraying foam we avoid thus any risk of passage of solution in the respiratory tract.
- the diffused foam is considered by many patients to be more acceptable and easier to use than a liquid form. But in the field of snoring where a daily treatment is necessary, the acceptability for the patients of this type of treatment is a very important factor of the observance and thus of the clinical success.
- Foam therefore constitutes a preferred dosage form of the anti-snore composition according to the invention.
- the anti-snoring composition is not limited in any way to this specific dosage form.
- the composition may especially be in solid form such as tablets, lozenges, chewing or disintegrating paste or any other solid form instantaneous disintegration.
- the composition may also be in liquid form such as in the form of gel, paste, toothpaste, solutions for the mouth, etc.
- the percentage by weight of each of the active agents present in the anti-snoring composition that is the subject of the invention is as follows:
- bioadhesive substance from 0.5 to 20%
- lubricating substance from 0.5 to 20%
- anti-inflammatory agent from approximately 0.5 to 8%
- tonic agent from 0.5 to 8% approximately.
- the percentage by weight of the bioadhesive substance will differ. Indeed, in the case where the composition is in the form of a foam, it will comprise about 1 to 5% of bioadhesive substance. In the case where the composition is in the solid form, it will comprise about 5 to 20% of bioadhesive substance.
- Carrageenans from 1 to about 5%, preferably 3%, Phosphatidylcholine from about 1 to about 10%, preferably about 5%
- Rose hip from 1 to 5%, preferably 2% Excipients: sweeteners, flavors, preservatives, water
- Bioadhesive was studied experimentally to verify its bioadhesive properties and to compare them with a non-bioadhesive reference substance (distilled water) and a marketed preparation (liposome preparation liposomes).
- the measurements that have been made are the flow time on a biological membrane and the immersion test with artificial saliva.
- the spreading time is the time taken by a defined volume of liquid to travel 10 cm on a plane inclined at 45 ° C. This test was performed at 3 levels: on a 20 cm 2 stainless steel plate, non-biological membrane. on a 20 cm 2 stainless steel plate covered with a cellulose membrane, biological membrane. on a stainless steel plate 20 cm 2 covered with a cellulose membrane itself impregnated with a 5% mucin solution.
- the immersion test in artificial saliva is intended to highlight the contact time of the product with the biological membrane when it is subjected to the action of saliva.
- the product is deposited on the surface of the covered biological membrane of mucin.
- the plate / biological membrane / product assembly is immersed vertically in a container containing 2 liters of artificial saliva.
- the time that the product persists on the surface of the membrane is determined by means of a stopwatch. The measured times are as follows:
- composition according to the invention has been experimentally studied in order to verify the synergy between the lubricating substance and the bioadhesive substance on its bioadhesion properties.
- the study carried out is the measurement of the previously defined spreading time, using different concentrations of a mixture of glycerol and 3% water (S2) as a lubricant for a given concentration of carrageenans (Sl) as a bioadhesive substance. .
- S2 glycerol and 3% water
- Sl carrageenans
- a 0.5 ml deposit was made 0.5 cm from the top edge of the plate, the deposit being made in a horizontal position. At 5 cm from the top edge of the plate is shown the stopwatch timing line when the liquid passes it after tilting the plate to 45 ° C. Similarly, 5 cm from the lower edge of the plate is shown the stop line stopwatch when the liquid crosses the latter.
- the ratio between the flow time and the S2 concentration shows a constant (1.9) for S2 concentrations up to 10%, then a significant increase for concentrations of the order of 16%. This clearly shows that for a given solution containing 2% carrageenans, the addition of glycerol exponentially increases the flow time, which is a measure of the bioadhesiveness of the final mixture.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL05807395T PL1802347T3 (pl) | 2004-10-20 | 2005-10-05 | Kompozycja przeciw chrapaniu |
DE602005014880T DE602005014880D1 (de) | 2004-10-20 | 2005-10-05 | Antischnarch-zusammensetzung |
US11/665,961 US20080069913A1 (en) | 2004-10-20 | 2005-10-05 | Anti-Snoring Composition |
BRPI0516394-3A BRPI0516394A (pt) | 2004-10-20 | 2005-10-05 | composição para combater o ronco |
CA002584276A CA2584276A1 (fr) | 2004-10-20 | 2005-10-05 | Composition pour lutter contre le ronflement |
DK05807395T DK1802347T3 (da) | 2004-10-20 | 2005-10-05 | Sammensætning til at bekæmpe snorken |
AU2005296930A AU2005296930A1 (en) | 2004-10-20 | 2005-10-05 | Anti-snoring composition |
EP05807395A EP1802347B1 (fr) | 2004-10-20 | 2005-10-05 | Composition pour lutter contre le ronflement |
MX2007004750A MX2007004750A (es) | 2004-10-20 | 2005-10-05 | Composicion para combatir el ronquido. |
JP2007537319A JP2008517041A (ja) | 2004-10-20 | 2005-10-05 | いびき防止組成物 |
AT05807395T ATE433330T1 (de) | 2004-10-20 | 2005-10-05 | Antischnarch-zusammensetzung |
IL182653A IL182653A0 (en) | 2004-10-20 | 2007-04-18 | Anti-snoring composition |
TNP2007000149A TNSN07149A1 (fr) | 2004-10-20 | 2007-04-19 | Composition pour lutter contre le ronflement |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0411153 | 2004-10-20 | ||
FR0411153A FR2876585B1 (fr) | 2004-10-20 | 2004-10-20 | Composition pour lutter contre le ronflement |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006042926A1 true WO2006042926A1 (fr) | 2006-04-27 |
Family
ID=34953515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/002444 WO2006042926A1 (fr) | 2004-10-20 | 2005-10-05 | Composition pour lutter contre le ronflement |
Country Status (22)
Country | Link |
---|---|
US (1) | US20080069913A1 (fr) |
EP (1) | EP1802347B1 (fr) |
JP (1) | JP2008517041A (fr) |
CN (1) | CN101068572A (fr) |
AT (1) | ATE433330T1 (fr) |
AU (1) | AU2005296930A1 (fr) |
BR (1) | BRPI0516394A (fr) |
CA (1) | CA2584276A1 (fr) |
CY (1) | CY1110518T1 (fr) |
DE (1) | DE602005014880D1 (fr) |
DK (1) | DK1802347T3 (fr) |
ES (1) | ES2328608T3 (fr) |
FR (1) | FR2876585B1 (fr) |
IL (1) | IL182653A0 (fr) |
MA (1) | MA29021B1 (fr) |
MX (1) | MX2007004750A (fr) |
PL (1) | PL1802347T3 (fr) |
PT (1) | PT1802347E (fr) |
RU (1) | RU2007118389A (fr) |
SI (1) | SI1802347T1 (fr) |
TN (1) | TNSN07149A1 (fr) |
WO (1) | WO2006042926A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010079305A1 (fr) | 2009-01-07 | 2010-07-15 | Polymerexpert Sa | Composition anti-ronflement contenant un polymère thermogélifiant |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2901705A1 (fr) * | 2006-06-01 | 2007-12-07 | Persee Medica Soc Par Actions | Composition pour lutter contre le ronflement se presentant sous la forme d'un spray nasal |
FR2901706A1 (fr) * | 2006-06-01 | 2007-12-07 | Persee Medica Soc Par Actions | Compositions nasale et buccale pour lutter contre le ronflement |
CN102019029B (zh) * | 2009-09-11 | 2014-04-30 | 坦纳医师联合股份有限公司 | 使用泵以递送用于减少打鼾的溶液 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2466273A1 (fr) * | 1979-10-03 | 1981-04-10 | Gonzales Maria | Emulsion notamment destinee a la fabrication de produits cosmetiques ou excipients pharmaceutiques et procede de fabrication d'une telle emulsion |
US4459285A (en) * | 1981-02-27 | 1984-07-10 | Societe Anonyme Dite: L'oreal | Cosmetic composition for the treatment of the hair and skin comprising a powder of flowers or flower tops and a cohesion agent |
JPS63169931A (ja) * | 1987-01-09 | 1988-07-13 | Nippon Oil & Fats Co Ltd | 低脂肪油中水型乳化油脂組成物 |
EP0507035A1 (fr) * | 1991-04-03 | 1992-10-07 | Synthelabo | Extraits de Reine des Prés, leur préparation et leurs applications |
KR20030063671A (ko) * | 2002-01-23 | 2003-07-31 | 주식회사 바이오레인 | 코골이 치료용 조성물 |
WO2003070178A2 (fr) * | 2002-02-15 | 2003-08-28 | Cns, Inc. | Pulverisateur pour la gorge |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0253728A (ja) * | 1988-08-17 | 1990-02-22 | Mieko Nakamura | いびき防止剤 |
JPH0692859A (ja) * | 1991-10-15 | 1994-04-05 | Sorubei Seiyaku Kk | いびき防止剤 |
CN1106259A (zh) * | 1994-02-05 | 1995-08-09 | 日东制药株式会社 | 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂 |
JPH10279491A (ja) * | 1997-04-01 | 1998-10-20 | Kao Corp | インターロイキン4産生抑制剤 |
US6187318B1 (en) * | 1998-10-29 | 2001-02-13 | Innovative Chemical Corporation | Anti-snoring composition |
US6455072B1 (en) * | 1999-10-28 | 2002-09-24 | Ingredient Innovations International | Stable aqueous dispersion of nutrients |
JP2002173425A (ja) * | 2000-12-07 | 2002-06-21 | Kao Corp | 喉ケア剤 |
US6790465B2 (en) * | 2000-12-01 | 2004-09-14 | Snore-Fix, Inc. | Composition and method for treating snoring |
-
2004
- 2004-10-20 FR FR0411153A patent/FR2876585B1/fr not_active Expired - Fee Related
-
2005
- 2005-10-05 DK DK05807395T patent/DK1802347T3/da active
- 2005-10-05 PT PT05807395T patent/PT1802347E/pt unknown
- 2005-10-05 BR BRPI0516394-3A patent/BRPI0516394A/pt not_active IP Right Cessation
- 2005-10-05 AU AU2005296930A patent/AU2005296930A1/en not_active Abandoned
- 2005-10-05 JP JP2007537319A patent/JP2008517041A/ja active Pending
- 2005-10-05 PL PL05807395T patent/PL1802347T3/pl unknown
- 2005-10-05 US US11/665,961 patent/US20080069913A1/en not_active Abandoned
- 2005-10-05 RU RU2007118389/15A patent/RU2007118389A/ru not_active Application Discontinuation
- 2005-10-05 CN CNA2005800411402A patent/CN101068572A/zh active Pending
- 2005-10-05 MX MX2007004750A patent/MX2007004750A/es not_active Application Discontinuation
- 2005-10-05 AT AT05807395T patent/ATE433330T1/de active
- 2005-10-05 EP EP05807395A patent/EP1802347B1/fr not_active Not-in-force
- 2005-10-05 ES ES05807395T patent/ES2328608T3/es active Active
- 2005-10-05 WO PCT/FR2005/002444 patent/WO2006042926A1/fr active Application Filing
- 2005-10-05 DE DE602005014880T patent/DE602005014880D1/de active Active
- 2005-10-05 CA CA002584276A patent/CA2584276A1/fr not_active Abandoned
- 2005-10-05 SI SI200530773T patent/SI1802347T1/sl unknown
-
2007
- 2007-04-18 IL IL182653A patent/IL182653A0/en unknown
- 2007-04-19 TN TNP2007000149A patent/TNSN07149A1/fr unknown
- 2007-05-14 MA MA29902A patent/MA29021B1/fr unknown
-
2009
- 2009-09-10 CY CY20091100946T patent/CY1110518T1/el unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2466273A1 (fr) * | 1979-10-03 | 1981-04-10 | Gonzales Maria | Emulsion notamment destinee a la fabrication de produits cosmetiques ou excipients pharmaceutiques et procede de fabrication d'une telle emulsion |
US4459285A (en) * | 1981-02-27 | 1984-07-10 | Societe Anonyme Dite: L'oreal | Cosmetic composition for the treatment of the hair and skin comprising a powder of flowers or flower tops and a cohesion agent |
JPS63169931A (ja) * | 1987-01-09 | 1988-07-13 | Nippon Oil & Fats Co Ltd | 低脂肪油中水型乳化油脂組成物 |
EP0507035A1 (fr) * | 1991-04-03 | 1992-10-07 | Synthelabo | Extraits de Reine des Prés, leur préparation et leurs applications |
KR20030063671A (ko) * | 2002-01-23 | 2003-07-31 | 주식회사 바이오레인 | 코골이 치료용 조성물 |
WO2003070178A2 (fr) * | 2002-02-15 | 2003-08-28 | Cns, Inc. | Pulverisateur pour la gorge |
Non-Patent Citations (2)
Title |
---|
LEONAVICIENE L ET AL: "AN IMPROVED MODEL OF OSTEOARTHRITIS IN RATS AND ITS THERAPY WITH THE TINCTURE OF FILIPENDULA ULMARIA (L.) MAXIM", BALTIC JOURNAL OF LABORATORY ANIMAL SCIENCE, COMPANY GRINDEX, RIGA, LV, vol. 11, no. 4, 2001, pages 225 - 237, XP001182640, ISSN: 1407-0944 * |
PATENT ABSTRACTS OF JAPAN vol. 012, no. 446 (C - 546) 24 November 1988 (1988-11-24) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010079305A1 (fr) | 2009-01-07 | 2010-07-15 | Polymerexpert Sa | Composition anti-ronflement contenant un polymère thermogélifiant |
Also Published As
Publication number | Publication date |
---|---|
CA2584276A1 (fr) | 2006-04-27 |
ES2328608T3 (es) | 2009-11-16 |
FR2876585A1 (fr) | 2006-04-21 |
DE602005014880D1 (de) | 2009-07-23 |
SI1802347T1 (sl) | 2009-12-31 |
FR2876585B1 (fr) | 2008-09-12 |
BRPI0516394A (pt) | 2008-09-02 |
JP2008517041A (ja) | 2008-05-22 |
US20080069913A1 (en) | 2008-03-20 |
CN101068572A (zh) | 2007-11-07 |
ATE433330T1 (de) | 2009-06-15 |
IL182653A0 (en) | 2007-07-24 |
MA29021B1 (fr) | 2007-11-01 |
TNSN07149A1 (fr) | 2008-11-21 |
RU2007118389A (ru) | 2008-11-27 |
AU2005296930A1 (en) | 2006-04-27 |
DK1802347T3 (da) | 2009-10-12 |
PT1802347E (pt) | 2009-09-16 |
MX2007004750A (es) | 2007-10-03 |
CY1110518T1 (el) | 2015-04-29 |
PL1802347T3 (pl) | 2010-03-31 |
EP1802347B1 (fr) | 2009-06-10 |
EP1802347A1 (fr) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Avon | Oral mucosal lesions associated with use of quid | |
US9549842B2 (en) | Buccal bioadhesive strip and method of treating snoring and sleep apnea | |
CA2308513C (fr) | Procede et composition permettant d'administrer du zinc ionique a une membrane nasale | |
US20100040712A1 (en) | Throat spray | |
EP1802347B1 (fr) | Composition pour lutter contre le ronflement | |
EP0392888B1 (fr) | Compositions thérapeutiques pour le traitement ou la prévention du ronflement | |
Bradley et al. | Saliva: its role in taste function | |
FR2825267A1 (fr) | Compositions pour l'hygiene buccale ou corporelle ou la proprete ou la sante comprenant des graines ou un broyat de graines ou un extrait de graines du genre moringa | |
FR2940761A1 (fr) | Composition anti-ronflement contenant un polymere thermogelifiant | |
EP2026835B1 (fr) | Compositions nasale et buccale comprenant un extrait de ruscus aculeatus de la rutine, pour lutter contre le ronflement | |
FR2649611A1 (fr) | Procede de preparation galenique d'une composition therapeutique notamment a base d'aspirine | |
EP3043783A1 (fr) | Complexe lubrifiant pour la bouche | |
FR2600535A1 (fr) | Nouvelle composition a base de lysozyme et de papaine pour l'hygiene et le confort de la cavite buccale. | |
EP2258354B1 (fr) | Composés et méthodes pour contrôler la prise d'alcool. | |
FR2901699A1 (fr) | Compositions dont les proprietes sont dues a l'association d'elements synergises, leur procede de preparation et leurs utilisations en cosmetique ou hygiene | |
JP2009286749A (ja) | 口腔衛生用固形物 | |
Branson | 101 Amazing Uses for Aloe Vera | |
JHANWAR et al. | Chewing Gum: Confectionary To a Popular Transbuccal Dosage Form | |
Revol et al. | Stomatologie gériatrique | |
CN109674719A (zh) | 复方中药鸡血藤牙膏及其制备方法 | |
FR2901705A1 (fr) | Composition pour lutter contre le ronflement se presentant sous la forme d'un spray nasal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2584276 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 182653 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/004750 Country of ref document: MX Ref document number: 2007537319 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005807395 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 554729 Country of ref document: NZ Ref document number: 2005296930 Country of ref document: AU Ref document number: 3056/DELNP/2007 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005296930 Country of ref document: AU Date of ref document: 20051005 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2007000301 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007118389 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580041140.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11665961 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005807395 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11665961 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0516394 Country of ref document: BR |